Helen K. Reddel
Helen K. Reddel is a respiratory physician and researcher who writes and edits on asthma and chronic obstructive pulmonary disease, with a focus on how real‑world data and evidence‑based guidelines translate into patient outcomes. Her work in the Medical Journal of Australia and other clinical journals is distinguished by large population surveys, detailed symptom and treatment metrics, and clear linkage between guideline strategy and everyday practice. She consistently uses longitudinal and nationally representative data to show where asthma care is worsening or improving, and what that means for health services and patients.
Asthma control in Australia
Reddel’s recurring subject in the Medical Journal of Australia is asthma control in adults, tracked through structured surveys and clinical instruments. In an earlier cross‑sectional web‑based survey of a nationally representative population, she reported the first broad data on asthma control and its relationship to treatment in Australia, showing that over half of respondents reported using preventer medication in the previous year and linking medication patterns to control levels. That study used a large sample and standardised measures to establish a baseline picture of how well asthma was being managed and how patients were using inhaled therapies across the country.
A decade later, she led a comparative analysis of stratified sample surveys in 2012 and 2021, published in the Medical Journal of Australia as “Worsening Asthma Outcomes in Australian Adults.” This work showed that symptom control was worse in 2021, with Asthma Control Test scores lower and 26.8% of participants classified as having very poorly controlled asthma. Across the same period, uncontrolled asthma rose from 46% to 52%, urgent healthcare use increased from 29% to 37%, and regular inhaled corticosteroid use fell, signalling a widening gap between recommended maintenance therapy and actual practice. By setting these surveys side by side, Reddel’s coverage highlights trends rather than single data points, making clear that key indicators of asthma care are moving in the wrong direction and quantifying the burden on acute services.
Global Initiative for Asthma strategy and evidence
Beyond national surveys, Reddel writes extensively on the Global Initiative for Asthma (GINA), drawing on her role as chair to explain how international strategies are built and updated. In the “Global Initiative for Asthma Strategy 2021” article, she summarises the core recommendations of the 2021 GINA report and the evidence behind major changes, giving clinicians a concise route into a large technical document. That piece emphasises GINA’s annually updated, evidence‑based approach to prevention and management, and walks readers through why certain treatment steps and reliever strategies have been revised based on new trial data.
Her 30‑year review of GINA, “Global initiative for asthma: 30 years of promoting evidence‑based care for asthma around the world,” traces how guideline‑driven care has evolved and how global collaboration has improved asthma outcomes. The article positions GINA as a living strategy rather than a static rulebook, highlighting the importance of regular evidence reviews and international consensus in refining recommendations. Reddel also co‑authors work on the shared vision between the Global Initiative for Asthma and the Global Initiative for Chronic Obstructive Pulmonary Disease, arguing for aligned strategies to address overlapping burdens of COPD and asthma worldwide and to respond to global challenges in chronic respiratory disease. Taken together, these pieces show her as a principal explainer of guideline shifts, making complex strategy documents usable for clinicians and health planners.
Chronic respiratory care and patient experience
Reddel’s writing frequently zooms in from system‑level metrics to the lived experience of people with chronic respiratory disease. In work on severe asthma, she examines symptom burden, health status and productivity in patients with uncontrolled versus controlled disease, documenting how poor control translates into missed work, impaired daily functioning and reduced quality of life. These analyses move beyond spirometry and exacerbation counts to include patient‑reported outcomes, underlining the economic and personal costs of inadequate control even in people receiving specialist therapies.
Her commentary “Action needed on asthma plans” argues for better implementation of written asthma action plans in primary care, linking simple planning tools to reductions in exacerbations and hospital visits. The piece calls out gaps in the use of action plans and reinforces their role as a practical bridge between guideline recommendations and what patients do at home during worsening symptoms. Across these articles, Reddel treats adherence, self‑management, and patient education as core components of respiratory care, not as secondary issues, and backs that stance with data on outcomes and healthcare utilisation.
Respiratory research leadership and data‑driven focus
Reddel writes from the standpoint of a senior respiratory researcher whose day‑to‑day work involves monitoring asthma and COPD at scale. Her research portfolio includes population monitoring of asthma and COPD and large multinational observational studies of disease features and treatment patterns, and that same quantitative depth is evident in her published analyses. She holds academic positions at Macquarie University and the University of Sydney and leads research in clinical management of asthma and COPD, which gives her direct access to emerging evidence across both specialist and primary care settings.
Her authorship record spans multiple respiratory and allergy journals on ScienceDirect, including practice‑focused titles that bridge research and front‑line care. She has been recognised with honours such as an Order of Australia for services to respiratory medicine and election to a national academy of health and medical sciences, underscoring her standing in the field she covers. In print, this translates to a style that is firmly data‑driven: she quantifies trends with large samples, uses validated instruments like the Asthma Control Test, and ties each finding back to concrete implications for treatment, guideline adherence and health‑system strain. Her coverage is narrow in subject but deep in evidence, making her writing particularly relevant for stories that need authoritative numbers and clear explanation of how global and national asthma strategies connect to everyday care.
4 more health journalists.
Abida Tasnim
Abida Tasnim is a health writer for The Daily Star who focuses on clear, practical guidance that helps readers recognise risks early and act before everyday illnesses turn into wider public health problems. She reports on infectious disease prevention, using measles coverage to show how outbreaks start with individual decisions and behaviours, not just hospital statistics. Her work explains what happens during an outbreak and then anchors the story in simple steps people can take, such as avoiding crowded places when symptoms appear, practising good hygiene, and seeking medical advice early. She writes direct, action‑oriented health explainers that turn clinical questions about contagion and disease burden into everyday choices. Across her beat, she stresses early recognition, timely care, and prevention as the foundations of healthier communities.
Adrián Carballo Casla
Adrián Carballo Casla stands out for turning complex cohort data on ageing into clear, food‑level advice on what older adults should eat to protect brain health and slow chronic disease. He is a researcher in nutritional epidemiology focused on ageing and chronic disease prevention and a postdoctoral researcher in geriatric epidemiology at Karolinska Institutet, writing health explainers for The Conversation. He reports on how diet quality, especially Mediterranean and Mind‑style patterns, shapes dementia risk, grey matter loss and neurocognitive ageing, and how healthy versus pro‑inflammatory diets alter multimorbidity trajectories. His articles translate findings on flavonoids, polyphenols, folate, omega‑3 fats and dietary nitrates into specific food choices and small, practical changes. Much of his coverage is anchored in his own studies on multimorbidity, high‑risk older adults and tailored dietary recommendations, often syndicated to other outlets.
Ahmed Elbediwy
Ahmed Elbediwy brings a lab-based understanding of cancer biology and clinical biochemistry to public-facing health reporting, linking drug mechanisms and molecular pathways to everyday choices about medicines and products. He writes for The Conversation on weight-loss injections, cancer overdiagnosis and anti-ageing supplements, focusing on obesity medicine, cancer signalling, screening trade-offs, skincare and supplement science. His pieces on GLP-1 drugs such as Ozempic, Wegovy and Mounjaro explain why some people do not respond, how gut hormones and appetite signals work, and where psychological support and nutrition fit alongside prescriptions. He co-authors explainers on cancer risk and overdiagnosis and on whether supplements can reverse ageing, separating established knowledge from emerging research. An award-winning senior lecturer at Kingston University, he favours clear, structured explainers, careful definition of key terms and evidence-based appraisal over hype.
Amanda Sheppeard
Amanda Sheppeard is a managing editor and health journalist known for long, detailed explainers that connect complex clinical research, disability policy and political narratives with the daily realities of doctors and patients. She works at The Medical Republic across editorial leadership and commercial content while reporting widely on medicine for its specialist titles. Her real beat spans autism, disability policy, autoimmune disease, infectious threats and system pressures in primary care and hospitals. She covers subjects such as autism diagnosis and the NDIS, rheumatology’s clinical shifts, weight-loss agents in rheumatoid arthritis, infection control, antimicrobial resistance and new modalities like CAR T-cell therapy and microneedles. She reports by doing the synthesis inside the story, linking trial design, molecular targets, funding rules and policy changes to concrete decisions and workflows in clinics and hospitals.